modelR03DA04

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:Theophylline
ATC code:R03DA04
route:oral
compartments:1
dosage:300mg
volume of distribution:0.45L
clearance:2.8mL/min/kg
other parameters in model implementation

Theophylline is a methylxanthine drug used as a bronchodilator in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. It has been largely supplanted by newer agents but is still used clinically, particularly for patients in whom inhaled therapies are not suitable.

Pharmacokinetics

Reported pharmacokinetics from healthy adult subjects following oral immediate-release administration.

References

  1. Ma, Y, et al., & Wang, L (2018). Population pharmacokinetics of theophylline in adult Chinese patients with asthma and chronic obstructive pulmonary disease. International journal of clinical pharmacy 40(5) 1010–1018. DOI:10.1007/s11096-018-0636-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29777329

  2. Moore, ES, et al., & Grasela, TH (1989). The population pharmacokinetics of theophylline in neonates and young infants. Journal of pharmacokinetics and biopharmaceutics 17(1) 47–66. DOI:10.1007/BF01059087 PUBMED:https://pubmed.ncbi.nlm.nih.gov/2715932

  3. Zandvliet, AS, et al., & Beijnen, JH (2005). Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. Basic & clinical pharmacology & toxicology 96(1) 71–79. DOI:10.1111/j.1742-7843.2005.pto960111.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/15667599

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)